Project Grant HT94252510214
Award Date
4/1/25
Completion Date
3/31/28
Dollars Obligated
$1.9M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Lubbock, TX 79430, USA
Similar Awards
This $1,124,825 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to identify novel therapeutic targets for aggressive prostate cancer through induced pluripotent stem cell modeling of BRCA2 mutant prostate tissue. The award, which runs from August 1, 2024 to July 31, 2027, will enable UTHSCSA to conduct innovative...
The federal Project Grant award provides $1,151,250.00 to Texas A&M University System Health Science Center to develop a unique small molecule for triple-negative breast cancer. The grant is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the public. The award period runs from July 1, 2024 to June 30, 2027....
This Project Grant award of $160,167.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of a peptide drug conjugate as a bone-targeted therapy for bone metastatic prostate cancer. The award was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, and will fund research activities at the cancer center from September 1, 2023 through August 24, 2024. The project...
This Project Grant award, valued at $159,341 and awarded on September 30, 2024, is funded through the Military Medical Research and Development program (CFDA 12.420) of the U.S. Department of the Army Medical Command. The grant supports research at The University of Texas Southwestern Medical Center in Dallas, Texas to target the PARP1 protein as a means of overcoming castration resistance in prostate cancer. The research aims to advance new treatment approaches for this condition, which is a...
The University of Texas Southwestern Medical Center was awarded a $1,467,321 project grant from the Defense Health Agency under the Military Medical Research and Development program. The grant will fund research from August 1, 2023 to July 31, 2026 to investigate the mechanisms controlling the progression of prostate adenocarcinoma to neuroendocrine cancer. As part of its mission to transform military and public health through innovative medical research solutions, the Defense Health Agency...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,560,000.00 in funding to the University of Texas Health Science Center at Houston (UTHealth) to develop drug conjugates of modified LGR4/5/6 ligands for cancer treatment. The award has a performance period from August 1, 2024 to July 31, 2027 and is aimed at advancing innovative medical treatments through biomedical research. UTHealth, a...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the...
The University of Texas Health Science Center of San Antonio (UTHSCSA) received a $978,159 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into purinergic receptor antagonist therapeutics for treating metastatic renal cancer from July 1, 2023 through June 30, 2026. As the prime awardee, UTHSCSA will conduct research to develop medical solutions for cancer on the battlefield...
The University of Texas Southwestern Medical Center was awarded a $1,376,914 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on the "Modulation Effect of Folate on the Association Between Inorganic Arsenic and Aggressive Prostate Cancer." This 3-year grant, with a start date of September 1, 2023, will support basic, applied, and advanced biomedical research to investigate potential medical...
This $1,189,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) aims to target stem-like CD8 T cells in immunotherapy against kidney cancer. The grant was awarded on September 1, 2023 to The University of Texas Southwestern Medical Center, an academic medical institution and component of the University of Texas System, to be completed by August 31, 2027. Through this funding, UT Southwestern will conduct research...